22 assets in Sezary Syndrome

Therapeutic assets addressing Sezary Syndrome, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Sezary Syndrome	Shanghai Jiao Tong University School of Medicine	P4	BB (70)
Prednisone Sezary Syndrome	Shanghai Jiao Tong University School of Medicine	P4	BB (68)
(+)-Vincristine Sezary Syndrome	Shanghai Jiao Tong University School of Medicine	P4	BB (68)
Mogamulizumab Sezary Syndrome	Kyowa Kirin Co., Ltd.	P2	B (62)
Brentuximab Vedotin Sezary Syndrome	City of Hope Medical Center	P2	B (61)
Resminostat Sezary Syndrome	4SC AG	P2	B (61)
Pembrolizumab Sezary Syndrome	Memorial Sloan Kettering Cancer Center	P2	B (57)
Fludarabine Sezary Syndrome	UNC Lineberger Comprehensive Cancer Center	P1/2	CCC (53)
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Sezary Syndrome	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Sezary Syndrome	National Cancer Institute (NCI)	P2	CCC (53)
Lenalidomide Sezary Syndrome	City of Hope Medical Center	P1/2	CCC (50)
Ritlecitinib Sezary Syndrome	Icahn School of Medicine at Mount Sinai	P2	CCC (50)
Aclarubicin Sezary Syndrome	Shanghai Jiao Tong University School of Medicine	P1/2	CC (45)
Durvalumab Sezary Syndrome	City of Hope Medical Center	P1/2	CC (45)
Fenretinide Sezary Syndrome	SciTech Development, Inc.	P1	CC (43)
Atlcar.Cd30.Ccr4 Cells Sezary Syndrome	UNC Lineberger Comprehensive Cancer Center	P1	CC (41)
Bendamustine Sezary Syndrome	UNC Lineberger Comprehensive Cancer Center	P1	CC (41)
Tulmimetostat Sezary Syndrome	Washington University School of Medicine	P1	CC (41)
Wu-Cart-007 Sezary Syndrome	Washington University School of Medicine	P1	CC (41)
dt-7012 Sezary Syndrome	Assistance Publique - Hôpitaux de Paris	Early P1	C (38)